Overview

Also Known As:Ahr null

These Ahr knock-out mice exhibit hepatic defects.

Donating Investigator

Christopher A Bradfield, University of Wisconsin-Madison

Genetic overview

Genetic Background	Generation

Ahr^tm1Bra

Allele Type	Gene Symbol	Gene Name
Targeted (Null/Knockout)	Ahr	aryl-hydrocarbon receptor

View Genetics

Research Applications

Developmental Biology Research
Hematological Research
Internal/Organ Research
Research Tools
Metabolism Research
Cancer Research

View All Research Applications

Base Price

Starting at:

$2,854.50 Domestic price Cryo Recovery

View Price List

Details

Detailed Description

Mice homozygous for the Ahr^tm1Bra targeted mutation are viable and fertile. Homozygotes do not respond to aryl-hydrocarbon receptor agonists. They show reduced liver weight (25% decrease) delayed extramedullary hematopoiesis, and transient hepatic microvesicular steatosis.

Development

The strain was developed using a construct that replaced exon 2 of the endogenous gene with the neomycin gene. The construct was electroporated into both (129X1/SvJ x 129S1/Sv)F1-derived R1 embryonic stem (ES) cells and CCE-derived 129S6/SvEvTac ES cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts and transfered into pseudopregnant CD1 foster mothers. Chimeric males were bred to C57BL/6 females. Heterozygous mice were bred to generate homozygotes.

Control Suggestions

Wild-type from the colony

Approximate Controls

101045 B6129SF2/J

Additional Information

Considerations for Choosing Controls

Selected References

Schmidt JV; Su GH; Reddy JK; Simon MC; Bradfield CA. 1996. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A 93(13):6731-6PubMed: 8692887 MGI: J:33827

View All References

Genetics

Ahr^tm1Bra

Allele Symbol: Ahr^tm1Bra

Allele Name	targeted mutation 1, Christopher A Bradfield
Allele Type	Targeted (Null/Knockout)
Allele Synonym(s)	Ahr^-; AhrKO
Gene Symbol and Name	Ahr, aryl-hydrocarbon receptor
Gene Synonym(s)
Strain of Origin	(129X1/SvJ x 129S1/Sv)F1-Kitl⁺
Chromosome	12
Molecular Note	A neomycin selection cassette replaced a genomic fragment containing exon 2, which encodes the basic-HLH domain essential for dimerization and DNA binding. Western blot analysis on liver cytosol demonstrated that the protein was not detectable in homozygous mice.
Mutations Made By	Christopher Bradfield, University of Wisconsin-Madison

Disease/Phenotype

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Genotype: Ahr^tm1Bra related

Developmental Biology Research
- Growth Defects
- Internal/Organ Defects
  - liver
Hematological Research
- Hematopoietic Defects
Internal/Organ Research
- Kidney Defects
- Liver Defects
Research Tools
- Toxicology Research
Metabolism Research
Cancer Research
- Toxicology

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
involves: 129S1/Sv * 129X1/SvJ

cardiovascular system phenotype

patent ductus venosus
- a patent ductus venosus (shunting blood around the liver) was seen in all mutants
- exposure to non-teratogenic concentration of dioxin on E18.5 did not result in closure of the ductus venosus in any mutants unlike in Ahr^tm3Bra homozygotes
- in all mice

integument phenotype

abnormal branching of the mammary ductal tree
- the number of terminal end buds is reduced by about 50% compared to littermate controls most ducts appear to be blunt ended or narrowed at the tip

reproductive system phenotype

abnormal ovarian folliculogenesis
- increased number of primordial follicles relative to wild-type at 2 to 3 days of age, similar numbers were observed in both mutant and wild-type ovaries between 8 and 53 days of age
- no increase in atresia relative to wild-type
- reduced numbers preantral and antral follicles
- reduced numbers preantral and antral follicles at 53 days of age

abnormal ovary physiology
- following treatment with a low dose equine chorionic gonadotropin (eCG) fewer corpora lutea are present compared to similarly treated controls

abnormal ovulation
- fewer corpora lutea by 45 days of age

abnormal superovulation
- following treatment with low doses of exogenous gonadotropins fewer oocytes are collected compared to similarly treated controls
- Normal - however, ovulation in response to higher doses of exogenous gonadotropins is similar to controls

decreased corpora lutea number
- fewer corpora lutea by 45 days of age

decreased germ cell number
- 70% reduction in the number of ovarian germ cells at 2 days of age
- similar number of germ cells as wild-type at E18

decreased ovary weight
- following treatment with a low dose equine chorionic gonadotropin (eCG) ovarian weights are significantly less than similarly treated controls
- Normal - however, in the absence of treatment or after treatment with a high dose of eCG ovarian weights are similar to controls

small ovary

cellular phenotype

decreased germ cell number
- 70% reduction in the number of ovarian germ cells at 2 days of age
- similar number of germ cells as wild-type at E18

patent ductus venosus
- a patent ductus venosus (shunting blood around the liver) was seen in all mutants
- exposure to non-teratogenic concentration of dioxin on E18.5 did not result in closure of the ductus venosus in any mutants unlike in Ahr^tm3Bra homozygotes
- in all mice

endocrine/exocrine gland phenotype

abnormal branching of the mammary ductal tree
- the number of terminal end buds is reduced by about 50% compared to littermate controls most ducts appear to be blunt ended or narrowed at the tip

abnormal ovarian folliculogenesis
- increased number of primordial follicles relative to wild-type at 2 to 3 days of age, similar numbers were observed in both mutant and wild-type ovaries between 8 and 53 days of age
- no increase in atresia relative to wild-type
- reduced numbers preantral and antral follicles
- reduced numbers preantral and antral follicles at 53 days of age

abnormal ovary physiology
- following treatment with a low dose equine chorionic gonadotropin (eCG) fewer corpora lutea are present compared to similarly treated controls

decreased corpora lutea number
- fewer corpora lutea by 45 days of age

decreased ovary weight
- following treatment with a low dose equine chorionic gonadotropin (eCG) ovarian weights are significantly less than similarly treated controls
- Normal - however, in the absence of treatment or after treatment with a high dose of eCG ovarian weights are similar to controls

small ovary

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
B6.129-Ahr/J

endocrine/exocrine gland phenotype

abnormal ovary physiology
- cultured fetal ovaries show a decrease in the number of apoptotic germ cells

abnormal primordial ovarian follicle morphology
- at P4 the number of primordial follicles is increased about 2 fold compared to littermate controls

immune system phenotype

abnormal chemokine level
- basal and 4 h post cigarette smoke exposure levels of CXCL2 and PGE2 are increased in BAL fluid relative to similarly treated controls
- levels of proinflammatory chemokines are increased in bronchoalveolar lavage (BAL) fluid

abnormal cytokine level
- levels of proinflammatory cytokines are increased in bronchoalveolar lavage (BAL) fluid

abnormal interleukin level
- increased levels of IL6 in BAL fluid

abnormal macrophage physiology
- Normal - exposure to an NFKB inhibitor (helenalin or SN50) blocks LPS induced IL6 and TNF expression in both mutant and wild-type mice
- macrophages from BAL fluid exposed to LPS in vitro produce more IL6 and TNF

abnormal tumor necrosis factor level
- both basal levels and expression 4 h after cigarette smoke exposure are increased in BAL fluid relative to similarly treated controls

increased susceptibility to bacterial infection
- inflammatory response in the lungs following aerosol exposure to LPS is increased compared to similarly treated controls
- macrophages from BAL fluid exposed to LPS in vitro produce more IL6 and TNF

lung inflammation
- following cigarette smoke exposure neutrophil influx into and beta-glucuronidase activity in the lungs are increased compared to similarly exposed wild-type controls
- following cigarette smoke exposure perivascular infiltrates are more pronounced
- inflammatory response in the lungs following aerosol exposure to LPS is increased compared to similarly treated controls
- lung inflammation after exposure to hyperoxia is increased compared to wild-type controls

hematopoietic system phenotype

abnormal macrophage physiology
- Normal - exposure to an NFKB inhibitor (helenalin or SN50) blocks LPS induced IL6 and TNF expression in both mutant and wild-type mice
- macrophages from BAL fluid exposed to LPS in vitro produce more IL6 and TNF

reproductive system phenotype

abnormal ovary physiology
- cultured fetal ovaries show a decrease in the number of apoptotic germ cells

abnormal primordial ovarian follicle morphology
- at P4 the number of primordial follicles is increased about 2 fold compared to littermate controls

respiratory system phenotype

lung inflammation
- following cigarette smoke exposure neutrophil influx into and beta-glucuronidase activity in the lungs are increased compared to similarly exposed wild-type controls
- following cigarette smoke exposure perivascular infiltrates are more pronounced
- inflammatory response in the lungs following aerosol exposure to LPS is increased compared to similarly treated controls
- lung inflammation after exposure to hyperoxia is increased compared to wild-type controls

pulmonary alveolar edema
- severe alveolar flooding after exposure to hyperoxia

pulmonary edema
- severe edema is seen after exposure to hyperoxia

homeostasis/metabolism phenotype

abnormal chemokine level
- basal and 4 h post cigarette smoke exposure levels of CXCL2 and PGE2 are increased in BAL fluid relative to similarly treated controls
- levels of proinflammatory chemokines are increased in bronchoalveolar lavage (BAL) fluid

abnormal cytokine level
- levels of proinflammatory cytokines are increased in bronchoalveolar lavage (BAL) fluid

abnormal enzyme/coenzyme activity
- basal hepatic methoxyresorufin O-demethylase (MROD) activity is reduced
- basal pulmonary ethoxyresorufin O-deethylase (EROD) activity is reduced and exposure to hyperoxia fails to increase pulmonary or hepatic EROD activity
- Normal - however, hyperoxia still induces an increase in MROD activity

abnormal interleukin level
- increased levels of IL6 in BAL fluid

abnormal tumor necrosis factor level
- both basal levels and expression 4 h after cigarette smoke exposure are increased in BAL fluid relative to similarly treated controls

increased physiological sensitivity to xenobiotic
- following cigarette smoke exposure neutrophil influx into and beta-glucuronidase activity in the lungs are increased compared to similarly exposed wild-type controls
- following cigarette smoke exposure perivascular infiltrates are more pronounced in the lungs

increased susceptibility to injury
- mice are more susceptible to hyperoxia induced lung injury with severe alveolar flooding, pulmonary edema, and increased lung inflammation

pulmonary alveolar edema
- severe alveolar flooding after exposure to hyperoxia

pulmonary edema
- severe edema is seen after exposure to hyperoxia

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
B6.129-Ahr

cardiovascular system phenotype

abnormal blood vessel morphology
- in the eye the limbal vasculature is exaggerated with loops that extend centrally and invade the corneal stroma

abnormal kidney blood vessel morphology
- vascular architecture is altered and appears less dense

abnormal liver sinusoid morphology
- sinusoids are highly anastomotic throughout the liver
- the sinusoidal pattern retains the neonatal structure with failure of the resolution of sinusoidal junctions that normally occurs during liver development

patent ductus venosus
- the ductus venosus remains open in adults resulting in portosystemic shunting and impaired liver perfusion

growth/size/body region phenotype

increased body weight
- 7% heavier than littermate controls of P90

homeostasis/metabolism phenotype

abnormal circulating hormone level
- serum concentration of 5alpha-androstane-3alpha,17beta-diol are reduced at P21

decreased physiological sensitivity to xenobiotic
- exposure to 2,3,7,8-tetrachrlorodibenzo-p-dioxin (TCDD) has no effect on anterior, ventral or dorsolateral prostate weights unlike in similarly exposed littermate controls
- exposure to TCDD increased rather than decreased seminal vesicle weight on P35
- Normal - however, by P90 seminal vesicle weight is reduced

liver/biliary system phenotype

abnormal hepatocyte morphology
- cytoplasmic area is reduced by nearly 50% compared to control littermates
- total cellular area is reduced by about 36% compared to control littermates

abnormal liver sinusoid morphology
- sinusoids are highly anastomotic throughout the liver
- the sinusoidal pattern retains the neonatal structure with failure of the resolution of sinusoidal junctions that normally occurs during liver development

decreased liver weight
- about a 25% reduction in relative liver weight compared to controls

renal/urinary system phenotype

abnormal kidney blood vessel morphology
- vascular architecture is altered and appears less dense

reproductive system phenotype

decreased seminal vesicle weight
- on P35 and P90

small prostate gland anterior lobe
- anterior prostate weight is reduced on P35 but not on P90

small prostate gland dorsolateral lobe
- dorsolateral prostate weight is reduced on P35 and P90

vision/eye phenotype

persistent hyaloid artery
- a persistent hyaloid artery is commonly seen
- in 25% of mice the hyaloid artery extends to the posterior lens capsule membrane

cellular phenotype

patent ductus venosus
- the ductus venosus remains open in adults resulting in portosystemic shunting and impaired liver perfusion

endocrine/exocrine gland phenotype

decreased seminal vesicle weight
- on P35 and P90

small prostate gland anterior lobe
- anterior prostate weight is reduced on P35 but not on P90

small prostate gland dorsolateral lobe
- dorsolateral prostate weight is reduced on P35 and P90

The following phenotype relates to a compound genotype created using this strain

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
involves: 129S1/Sv * 129X1/SvJ * C57BL/6

cardiovascular system phenotype

patent ductus venosus

hematopoietic system phenotype

abnormal Langerhans cell morphology
- expression analysis indicates impaired maturation after 3 days in culture
- immature cells are slightly smaller and remain of lower granularity after maturation compared to controls

decreased spleen germinal center size
- smaller germinal centers

enlarged spleen
- ~50% increase in mononuclear cell numbers at 6 weeks of age, but not at 2 or 3 weeks of age
- exhibited by ~50% at 6 weeks of age
- increased erythroid component

extramedullary hematopoiesis
- occuring in postnatal livers
- varying penetrance, tending to be milder in livers with more severe fatty metamorphosis

homeostasis/metabolism phenotype

decreased physiological sensitivity to xenobiotic
- resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced toxicity; mutants do not exhibit hepatomegaly, thymic involution or cleft palate formation in response to TCDD administration

immune system phenotype

abnormal cytokine secretion
- secretion of granulocyte macrophage colony stimulating factor (CSF2) is reduced in cultured epidermal cells (about 90% keratinocytes)

abnormal Langerhans cell morphology
- expression analysis indicates impaired maturation after 3 days in culture
- immature cells are slightly smaller and remain of lower granularity after maturation compared to controls

abnormal Langerhans cell physiology
- after 45, but not after 90, minutes in culture phagocytic activity is increased
- expression of CD24a is reduced on immature and mature Langerhans cells

decreased spleen germinal center size
- smaller germinal centers

decreased susceptibility to type IV hypersensitivity reaction
- the increase in ear thickness following exposure to fluorescein isothiocyanate (FITC) is decreased compared to similarly treated controls

enlarged spleen
- ~50% increase in mononuclear cell numbers at 6 weeks of age, but not at 2 or 3 weeks of age
- exhibited by ~50% at 6 weeks of age
- increased erythroid component

cellular phenotype

patent ductus venosus

integument phenotype

abnormal keratinocyte physiology
- secretion of granulocyte macrophage colony stimulating factor (CSF2) is reduced in cultured epidermal cells (about 90% keratinocytes)

endocrine/exocrine gland phenotype

abnormal primordial ovarian follicle morphology
- at P4 the number of primordial follicles is increased about 2 fold compared to littermate controls

liver/biliary system phenotype

decreased liver weight
- reduced liver weight (28% less than wild-type)

hepatic steatosis
- evidence of fatty metamorphosis dissipated by 3 weeks of age
- extensive microvesicular fatty metamorphosis that was neither consistently pericentral or periportal

liver hyperplasia
- hypercellularity with thickening and fibrosis in portal regions by 2 weeks of age

microvesicular hepatic steatosis
- evidence of fatty metamorphosis dissipated by 3 weeks of age
- extensive microvesicular fatty metamorphosis that was neither consistently pericentral or periportal

pale liver
- evident prior to 2 weeks of age

small liver

reproductive system phenotype

abnormal primordial ovarian follicle morphology
- at P4 the number of primordial follicles is increased about 2 fold compared to littermate controls

growth/size/body region phenotype

decreased body weight

enlarged spleen
- ~50% increase in mononuclear cell numbers at 6 weeks of age, but not at 2 or 3 weeks of age
- exhibited by ~50% at 6 weeks of age
- increased erythroid component

liver hyperplasia
- hypercellularity with thickening and fibrosis in portal regions by 2 weeks of age

postnatal growth retardation

References

Schmidt JV; Su GH; Reddy JK; Simon MC; Bradfield CA. 1996. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A 93(13):6731-6PubMed: 8692887 MGI: J:33827

Additional References

Lahvis GP; Bradfield CA. 1998. Ahr null alleles: distinctive or different? Biochem Pharmacol 56(7):781-7PubMed: 9774139 MGI: J:49883

Additional - Ahr^tm1Bra related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Separated PCR:Ahr
- Standard PCR:Ahr Alternate 1
- Genotyping resources and troubleshooting
Breeding Considerations

Homozygous females are poor mothers and have small litters. When maintaining a live colony, this strain can be maintained by heterozygous sibling matings. Expected coat color from breeding:Black
- Additional Breeding and Husbandry Support
Appearance
- black
  Related Genotype: a/a
Citation
When using the Ahr null mouse strain in a publication, please cite the originating article(s) and include JAX stock #002727 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Pricing & Availability

Cryo Recovery

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service/Product	Description	Price
	Heterozygous or Wild-type for Ahr<tm1Bra>

Related Products and Services

Frozen Mouse Embryo	B6;129-Ahr<tm1Bra>/J	$2595.00
Frozen Mouse Embryo	B6;129-Ahr<tm1Bra>/J	$2595.00
Frozen Mouse Embryo	B6;129-Ahr<tm1Bra>/J	$3373.50
Frozen Mouse Embryo	B6;129-Ahr<tm1Bra>/J	$3373.50

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.

Terms Of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As:Ahr null

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Control Suggestions

Approximate Controls

Additional Information

Selected References

Ahrtm1Bra

Allele Symbol: Ahrtm1Bra

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Genotype: Ahrtm1Bra related

Mammalian Phenotype Terms by Genotype

Genotype: Ahrtm1Bra/Ahrtm1Brainvolves: 129S1/Sv * 129X1/SvJ

cardiovascular system phenotype

integument phenotype

reproductive system phenotype

cellular phenotype

endocrine/exocrine gland phenotype

Genotype: Ahrtm1Bra/Ahrtm1BraB6.129-Ahr/J

endocrine/exocrine gland phenotype

immune system phenotype

hematopoietic system phenotype

reproductive system phenotype

respiratory system phenotype

homeostasis/metabolism phenotype

Genotype: Ahrtm1Bra/Ahrtm1BraB6.129-Ahr

cardiovascular system phenotype

growth/size/body region phenotype

homeostasis/metabolism phenotype

liver/biliary system phenotype

renal/urinary system phenotype

reproductive system phenotype

vision/eye phenotype

cellular phenotype

endocrine/exocrine gland phenotype

Genotype: Ahrtm1Bra/Ahrtm1Brainvolves: 129S1/Sv * 129X1/SvJ * C57BL/6

cardiovascular system phenotype

hematopoietic system phenotype

homeostasis/metabolism phenotype

immune system phenotype

cellular phenotype

integument phenotype

endocrine/exocrine gland phenotype

liver/biliary system phenotype

reproductive system phenotype

growth/size/body region phenotype

References

Additional References

Additional - Ahrtm1Bra related

Genotyping Protocols

Breeding Considerations

Appearance

Citation

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Live Mouse

Cryorecovery - Pricing

Related Products and Services

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms Of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Ahr^tm1Bra

Allele Symbol: Ahr^tm1Bra

Genotype: Ahr^tm1Bra related

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
involves: 129S1/Sv * 129X1/SvJ

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
B6.129-Ahr/J

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
B6.129-Ahr

Genotype: Ahr^tm1Bra/Ahr^tm1Bra
involves: 129S1/Sv * 129X1/SvJ * C57BL/6

Additional - Ahr^tm1Bra related